FierceBiotechOriginal article
{"a":[{"_":"Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes","$":{"href":"/biotech/roches-glp-1gip-drug-hits-phase-2-diabetes-trial-fueling-best-disease-prediction","hreflang":"en"}}]}
Phase 2positiveGLP-1/GIP receptor agonistPositive
AI Analysis
Summary
Roche's dual GLP-1/GIP receptor agonist met primary endpoints in a Phase 2 diabetes trial, positioning it as a potential treatment for Type 2 diabetes and obesity.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Phase 2 trial hit primary endpoints
Importance:7/10
Sentiment:
0.75
GLP-1GIPType 2 diabetesobesitydual agonist
Related Companies
Read the original article
Published by FierceBiotech on September 22, 2026 4:06 AM